Genome-Wide Association Study and Gene-Based Analysis of Participants With Hemophilia A and Inhibitors in the My Life, Our Future Research Repository

Samuel Lessard; Chunla He; Deepak K Rajpal; Katherine Klinger; Christine Loh; Tim Harris; Jennifer Dumont

doi:10.3389/fmed.2022.903838

Genome-Wide Association Study and Gene-Based Analysis of Participants With Hemophilia A and Inhibitors in the My Life, Our Future Research Repository

Front Med (Lausanne). 2022 Jun 23:9:903838. doi: 10.3389/fmed.2022.903838. eCollection 2022.

Authors

Samuel Lessard¹, Chunla He², Deepak K Rajpal¹, Katherine Klinger¹, Christine Loh³, Tim Harris³, Jennifer Dumont⁴

Affiliations

¹ Sanofi S.A., Framingham, MA, United States.
² American Thrombosis and Hemostasis Network, Rochester, NY, United States.
³ Bioverativ, a Sanofi Company, Waltham, MA, United States.
⁴ Sanofi S.A., Cambridge, MA, United States.

Abstract

Introduction: Up to 30% of individuals with hemophilia A develop inhibitors to replacement factor VIII (FVIII), rendering the treatment ineffective. The underlying mechanism of inhibitor development remains poorly understood. The My Life, Our Future Research Repository (MLOF RR) has gathered F8 and F9 mutational information, phenotypic data, and biological material from over 11,000 participants with hemophilia A (HA) and B as well as carriers enrolled across US hemophilia treatment centers, including over 5,000 whole-genome sequences. Identifying genes associated with inhibitors may contribute to our understanding of why certain patients develop those neutralizing antibodies.

Aim and methods: Here, we performed a genome-wide association study and gene-based analyses to identify genes associated with inhibitors in participants with HA from the MLOF RR.

Results: We identify a genome-wide significant association within the human leukocyte antigen (HLA) locus in participants with HA with F8 intronic inversions. HLA typing revealed independent associations with the HLA alleles major histocompatibility complex, class II, DR beta 1 (HLA DRB1*15:01) and major histocompatibility complex, class II, DQ beta 1 (DQB1*03:03). Variant aggregation tests further identified low-frequency variants within GRID2IP (glutamate receptor, ionotropic, delta 2 [GRID2] interacting protein 1) significantly associated with inhibitors.

Conclusion: Overall, our study confirms the association of DRB1*15:01 with FVIII inhibitors and identifies a novel association of DQB1*03:03 in individuals with HA carrying intronic inversions of F8. In addition, our results implicate GRID2IP, encoding GRID2-interacting protein, with the development of inhibitors, and suggest an unrecognized role of this gene in autoimmunity.

Keywords: genome-wide association study; hemophilia A; humans; inhibitors; major histocompatibility complex; whole-genome sequencing.